OncoMatch/Clinical Trials/NCT05749289

Application of Al18F-octreotide PET/CT in Neuroendocrine Tumor

Is NCT05749289 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies Al18F-octreotide for neuroendocrine tumor.

Phase 2/3RecruitingCancer Institute and Hospital, Chinese Academy of Medical SciencesNCT05749289Data as of May 2026

Treatment: Al18F-octreotide — This is an open-label whole-body PET/CT study for investigating the value of Al18F-octreotide PET/CT in patients with Neuroendocrine Tumor

Check if I qualify

Extracted eligibility criteria

Cancer type

Neuroendocrine Tumor

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify